Overview

Microorganisms, immunology, and vaccines form a high-yield area in UPSC Prelims (Science & Technology) and GS3 Mains. Questions frequently test the differences among bacteria, viruses, fungi, and protozoa; the mechanism of vaccines; India's immunization programmes (Mission Indradhanush, UIP); and the growing crisis of antimicrobial resistance (AMR). A solid understanding of these topics also helps in answering current-affairs questions on pandemics, new vaccines, and One Health initiatives.


1. Types of Microorganisms

Microorganisms (microbes) are living organisms too small to be seen with the naked eye. They are broadly classified into four groups: bacteria, viruses, fungi, and protozoa.

1.1 Bacteria

  • Cell type: Prokaryotic — lack a membrane-bound nucleus and membrane-bound organelles.
  • Size: Typically 0.5--10 µm.
  • Cell wall: Made of peptidoglycan. Gram staining classifies bacteria into Gram-positive (thick peptidoglycan layer, stains violet) and Gram-negative (thin peptidoglycan layer with outer lipid membrane, stains pink).
  • Shapes:
Shape Description Example
Cocci Spherical Staphylococcus aureus, Streptococcus pneumoniae
Bacilli Rod-shaped Escherichia coli, Mycobacterium tuberculosis
Spirilla Rigid spiral Helicobacter pylori
Vibrio Comma-shaped Vibrio cholerae (cholera)
Spirochetes Thin, flexible spiral Treponema pallidum (syphilis)
  • Reproduction: Primarily by binary fission (asexual). Genetic variation occurs through conjugation, transformation, and transduction.

1.2 Viruses

  • Not truly living: Viruses are acellular — they lack cells, ribosomes, and metabolic machinery. They are metabolically inert outside a host cell and can only replicate inside living host cells.
  • Structure: A core of nucleic acid (DNA or RNA, never both) surrounded by a protein coat called a capsid. Some viruses have an outer envelope derived from the host cell membrane.
  • Classification by genetic material:
    • DNA viruses — Adenovirus, Herpesvirus, Poxvirus, Hepatitis B virus.
    • RNA viruses — Influenza virus, SARS-CoV-2, HIV, Dengue virus, Rabies virus, Hepatitis C virus.
  • Size: Much smaller than bacteria — typically 20--300 nm.
  • Bacteriophages are viruses that specifically infect bacteria.

1.3 Fungi

  • Cell type: Eukaryotic — have a membrane-bound nucleus and organelles.
  • Cell wall: Made of chitin (not peptidoglycan like bacteria).
  • Modes of nutrition: Heterotrophic — mainly saprotrophic (decomposers of dead organic matter). Some are parasitic; some are symbiotic (e.g., mycorrhizae with plant roots, lichens with algae/cyanobacteria).
  • Examples: Yeasts (unicellular), moulds (Penicillium, Aspergillus), mushrooms (multicellular).
  • Reproduction: Spore formation (sexual and asexual), budding (yeasts), fragmentation.

1.4 Protozoa

  • Cell type: Unicellular eukaryotes.
  • Habitat: Mostly aquatic (freshwater, marine) or parasitic within hosts.
  • Movement-based classification:
    • Amoeboids (pseudopodia) — Entamoeba histolytica (amoebic dysentery).
    • Flagellates (flagella) — Trypanosoma (sleeping sickness), Giardia.
    • Ciliates (cilia) — Paramecium.
    • Sporozoans (non-motile, spore-forming) — Plasmodium (malaria).

2. Beneficial Microorganisms

Not all microorganisms are harmful. Many play essential roles in food production, agriculture, medicine, and environmental cleanup.

2.1 Food & Fermentation

Application Microorganism Product
Curd/yoghurt Lactobacillus (bacteria) Lactic acid ferments milk
Bread, wine, beer Saccharomyces cerevisiae (yeast) Ethanol + CO2 via alcoholic fermentation
Vinegar Acetobacter (bacteria) Acetic acid from ethanol
Cheese Various bacteria and moulds Ripening and flavour development
Idli/dosa batter Yeast + Leuconostoc mesenteroides CO2 leavening, slight fermentation

2.2 Nitrogen Fixation

  • Rhizobium bacteria form a symbiotic association with roots of leguminous plants (peas, beans, groundnut, clover). They colonise root cells, forming root nodules, and convert atmospheric nitrogen (N2) into ammonia (NH3) using the enzyme nitrogenase. The plant supplies organic acids as a carbon source; in return, the bacteria supply usable nitrogen.
  • Azotobacter and Clostridium are free-living nitrogen-fixing soil bacteria.
  • Cyanobacteria (e.g., Anabaena, Nostoc) fix nitrogen in rice paddies and are important biofertilisers.

2.3 Antibiotics

  • Alexander Fleming discovered penicillin in September 1928 when he observed that the mould Penicillium notatum (now reclassified as Penicillium rubens) inhibited the growth of Staphylococcus bacteria on a petri dish.
  • Howard Florey and Ernst Boris Chain later developed methods for large-scale production of penicillin during World War II. All three shared the 1945 Nobel Prize in Physiology or Medicine.
  • Antibiotics work only against bacteria, not viruses. Misuse of antibiotics against viral infections contributes to antimicrobial resistance.

2.4 Bioremediation

  • Use of microorganisms to clean up environmental pollutants such as oil spills, heavy metals, and pesticides.
  • Pseudomonas species are widely used in bioremediation of hydrocarbons and toxic compounds.
  • Alcanivorax borkumensis is a naturally occurring marine bacterium that degrades oil hydrocarbons.

3. Infectious Diseases

Diseases caused by pathogenic microorganisms that can be transmitted from one person to another or through vectors.

3.1 Disease Summary Table

Disease Causative Agent Type Transmission
Tuberculosis (TB) Mycobacterium tuberculosis Bacteria Airborne droplets
Cholera Vibrio cholerae Bacteria Contaminated water/food
Typhoid Salmonella typhi Bacteria Contaminated water/food
Pneumonia Streptococcus pneumoniae and others Bacteria Airborne droplets
COVID-19 SARS-CoV-2 Virus (RNA) Respiratory droplets, aerosol
Dengue Dengue virus (Flavivirus) Virus (RNA) Aedes aegypti mosquito bite
Influenza Influenza virus Virus (RNA) Airborne droplets
Rabies Rabies virus (Lyssavirus) Virus (RNA) Bite of infected animal
Hepatitis B Hepatitis B virus Virus (DNA) Blood, body fluids
Ringworm Trichophyton, Microsporum Fungus Direct contact, fomites
Malaria Plasmodium spp. (P. falciparum, P. vivax) Protozoa Anopheles mosquito bite
Amoebic dysentery Entamoeba histolytica Protozoa Contaminated water/food

Exam Tip: Remember that antibiotics are effective ONLY against bacterial infections. Viral diseases require antivirals; fungal diseases need antifungals. This distinction is frequently tested in UPSC Prelims.


4. The Immune System

The immune system is the body's defence mechanism against pathogens. It has two main branches: innate (non-specific) and adaptive (specific) immunity.

4.1 Innate Immunity (Non-specific)

  • Present from birth; does not require prior exposure to a pathogen.
  • Provides the first and second lines of defence.
  • First line: Physical barriers — skin, mucous membranes, stomach acid, saliva, tears (contain lysozyme).
  • Second line: Cellular and chemical defences — phagocytes (neutrophils, macrophages), natural killer (NK) cells, inflammation, fever, complement system, interferons.
  • Response is rapid (minutes to hours) but does not develop memory.

4.2 Adaptive Immunity (Specific)

  • Develops after exposure to a specific antigen; takes days to activate on first encounter.
  • Key feature: Immunological memory — faster, stronger response upon re-exposure (basis of vaccination).
  • Two arms:
    • Humoral immunity (B-cell mediated) — B-lymphocytes produce antibodies (immunoglobulins) that circulate in blood and neutralise extracellular pathogens.
    • Cell-mediated immunity (T-cell mediated) — T-lymphocytes directly attack infected cells.

4.3 Key Immune Cells

Cell Type Origin Function
B-cells Bone marrow (mature in bone marrow) Produce antibodies; some become memory B-cells
Helper T-cells (CD4+) Bone marrow (mature in thymus) Activate B-cells and cytotoxic T-cells; coordinate immune response
Cytotoxic T-cells (CD8+) Bone marrow (mature in thymus) Kill virus-infected cells and tumour cells
Memory cells Derived from B-cells and T-cells Persist long-term; enable rapid secondary immune response
Macrophages Bone marrow (monocyte-derived) Phagocytose pathogens; present antigens to T-cells
Natural Killer (NK) cells Bone marrow Innate immunity; destroy virus-infected and cancerous cells

4.4 Antibodies (Immunoglobulins)

Antibodies are Y-shaped proteins produced by B-cells. Each antibody has an antigen-binding site specific to one antigen. There are five classes:

Class Percentage of serum Ig Key Features
IgG ~75% Most abundant; crosses the placenta (provides passive immunity to foetus); long-lasting; activates complement
IgM ~10% First antibody produced in a primary immune response; pentameric structure (5 units); strong agglutinator
IgA ~15% Found in secretions (saliva, tears, breast milk, mucus); protects mucosal surfaces
IgE Trace Involved in allergic reactions and defence against parasitic worms; binds to mast cells and basophils, triggering histamine release
IgD Trace Found on surface of mature B-cells; functions as an antigen receptor; role in immune surveillance

Exam Tip: For UPSC, remember: IgG crosses the placenta, IgA is in secretions (breast milk protects newborns), IgM is the first responder, and IgE causes allergies.

4.5 Antigens vs Antibodies

  • Antigen: Any substance (usually a protein on the surface of a pathogen) that triggers an immune response.
  • Antibody: A protein produced by B-cells that specifically binds to an antigen and helps neutralise or destroy the pathogen.

5. Vaccines

A vaccine is a biological preparation that provides active acquired immunity to a specific infectious disease. Vaccines contain an agent resembling a disease-causing microorganism, which stimulates the immune system to recognise it as a threat, produce antibodies, and develop memory cells for future rapid response.

5.1 Types of Vaccines

Type Mechanism Examples
Live attenuated Weakened (attenuated) form of the live pathogen; strong immune response, often lifelong BCG (TB), MMR, Oral Polio (OPV), Yellow Fever
Inactivated (killed) Pathogen killed by heat or chemicals; safer but weaker response; may need boosters Rabies vaccine, Inactivated Polio (IPV), Hepatitis A, Covaxin (COVID-19)
Subunit / Recombinant Contains only specific protein fragments (antigens) of the pathogen, not the whole organism Hepatitis B (recombinant), HPV vaccine, Corbevax (COVID-19)
Toxoid Inactivated toxin (not the bacterium itself) used when the toxin causes the disease Tetanus toxoid, Diphtheria toxoid
Viral vector Uses a harmless virus (vector) to deliver genetic material encoding a pathogen's antigen into host cells Covishield/AstraZeneca (COVID-19), Sputnik V
mRNA Synthetic mRNA encoding the pathogen's antigen (e.g., spike protein); host cells produce the protein, triggering immune response; mRNA does NOT enter the cell nucleus or alter DNA Pfizer-BioNTech (Comirnaty), Moderna (Spikevax)

5.2 India's COVID-19 Vaccines

Vaccine Developer Platform Key Detail
Covishield Serum Institute of India (SII) under licence from Oxford-AstraZeneca Viral vector (chimpanzee adenovirus) Most widely used in India's COVID vaccination drive
Covaxin (BBV152) Bharat Biotech + ICMR-NIV Whole-virion inactivated India's first indigenous COVID-19 vaccine
Corbevax Biological E (licence from Baylor College of Medicine / Texas Children's Hospital) Protein subunit (receptor binding domain of spike protein) First protein subunit COVID vaccine approved in India

6. India's Immunization Programme

6.1 Universal Immunization Programme (UIP)

  • Launched: 1985 by the Government of India under the Ministry of Health and Family Welfare.
  • Objective: Provide free vaccination to all children and pregnant women across the country.
  • Coverage: One of the largest immunization programmes in the world, targeting approximately 2.67 crore newborns and 2.9 crore pregnant women annually.
  • Diseases covered (currently 12): Tuberculosis, Diphtheria, Pertussis (Whooping Cough), Tetanus, Poliomyelitis, Measles, Hepatitis B, Rotaviral Gastroenteritis, Japanese Encephalitis (endemic areas), Rubella, Pneumonia caused by Haemophilus influenzae type B, and Pneumococcal diseases.

6.2 Key Vaccines in UIP Schedule

Age Vaccines Given
At birth BCG, OPV-0 (zero dose), Hepatitis B (birth dose)
6 weeks OPV-1, Pentavalent-1 (DPT + Hep B + Hib), fIPV-1, Rotavirus-1, PCV-1
10 weeks OPV-2, Pentavalent-2, Rotavirus-2
14 weeks OPV-3, Pentavalent-3, fIPV-2, Rotavirus-3, PCV-2
9--12 months Measles-Rubella (MR-1), PCV booster, JE-1 (endemic areas), Vitamin A (1st dose)
16--24 months MR-2, JE-2 (endemic areas), DPT booster-1, OPV booster
5--6 years DPT booster-2
10 years Tetanus-Diphtheria (Td)
16 years Td booster

6.3 Mission Indradhanush

  • Launched: 25 December 2014 by Union Health Minister J.P. Nadda.
  • Objective: Achieve at least 90% full immunization coverage by reaching unvaccinated and partially vaccinated children and pregnant women, especially in underserved and hard-to-reach areas.
  • Focus: Initially identified 201 high-focus districts (later expanded) with the highest number of partially immunised and unimmunised children.
  • Impact: Between 2014 and 2018, India's annual immunisation growth rate rose to 6.7% — a significant jump from the earlier rate of about 1% per year.

6.4 Intensified Mission Indradhanush (IMI)

Phase Launch Date Key Focus
IMI 1.0 8 October 2017 (by PM Modi) Reach unreached populations; targeted 173 districts and 17 urban areas
IMI 2.0 December 2019 Accelerate coverage in identified blocks and districts
IMI 3.0 February 2021 250 pre-identified districts/urban areas across 29 States/UTs
IMI 4.0 7 February 2022 416 districts across 33 States/UTs; three rounds
IMI 5.0 2023 Special focus on Measles-Rubella coverage; all districts in the country; children up to 5 years

7. Antibiotic Resistance (AMR)

7.1 What is AMR?

Antimicrobial Resistance (AMR) occurs when microorganisms (bacteria, viruses, fungi, parasites) evolve to resist the drugs designed to kill them. When bacteria become resistant to antibiotics, infections become harder or impossible to treat, leading to longer illness, higher medical costs, and increased mortality.

7.2 Causes of AMR

  • Overuse and misuse of antibiotics in humans (self-medication, incomplete courses).
  • Over-the-counter availability of antibiotics without prescription (widespread in India).
  • Overuse in agriculture and animal husbandry — antibiotics used as growth promoters in livestock and poultry.
  • Poor infection control in hospitals (healthcare-associated infections).
  • Inadequate sanitation and hygiene — leading to greater spread of resistant organisms.
  • Lack of new antibiotic development — the antibiotic pipeline has slowed since the 1980s.

7.3 Superbugs

  • Superbugs are strains of bacteria that have become resistant to multiple antibiotics.
  • Examples: MRSA (Methicillin-Resistant Staphylococcus aureus), NDM-1-producing bacteria (New Delhi Metallo-beta-lactamase, first identified in 2009), extensively drug-resistant TB (XDR-TB).
  • WHO classifies AMR as one of the top 10 global public health threats.

7.4 India's Response to AMR

National Action Plan on AMR (NAP-AMR) 2017--2021:

  • Released in April 2017 by the Ministry of Health and Family Welfare, aligned with the WHO Global Action Plan on AMR.
  • Six strategic priorities: (1) Improve awareness and understanding through communication and education; (2) Strengthen surveillance; (3) Reduce infection through prevention and control; (4) Optimise use of antimicrobials; (5) Promote research and innovation; (6) Strengthen India's leadership on AMR.
  • Adopts the One Health approach — recognising that AMR must be tackled across human health, animal health, agriculture, fisheries, and the environment simultaneously.

ICMR AMR Surveillance Network (AMRSN):

  • Established in 2013 by the Indian Council of Medical Research (ICMR).
  • Monitors drug-resistant infection patterns across Indian hospitals.
  • Expanded from 4 nodal centres initially to 21 centres, collecting over 4 lakh patient records.
  • Publishes annual AMR surveillance reports; the data guides treatment guidelines and new drug development.

Other Measures:

  • Red Line Campaign — antibiotics that should not be sold without prescription are marked with a red vertical line on the packaging.
  • Schedule H1 — restricts over-the-counter sale of certain antibiotics; mandates prescription record-keeping by pharmacists.

7.5 One Health Approach

The One Health approach recognises the interconnection between the health of humans, animals, and the environment. AMR bacteria can transfer between animals and humans through the food chain, direct contact, or shared environments. Effective AMR control requires coordinated action across all three domains — this principle is central to both the WHO Global Action Plan and India's NAP-AMR.


8. UPSC Relevance

Key Areas for Prelims

  • Classification of microorganisms (prokaryotic vs eukaryotic, DNA vs RNA viruses).
  • Differences among types of vaccines (live attenuated vs inactivated vs subunit vs mRNA).
  • Diseases and their causative agents (bacterial vs viral vs protozoan).
  • India's immunization programmes — UIP, Mission Indradhanush, IMI phases.
  • Antibody types and their functions (IgG crosses placenta, IgA in secretions).

Key Areas for Mains (GS3)

  • AMR as a public health crisis — causes, consequences, and India's NAP-AMR.
  • One Health approach and its relevance to AMR, zoonotic diseases, and pandemic preparedness.
  • India's vaccination policy — successes of UIP and Mission Indradhanush, remaining challenges.
  • Science & Technology questions on mRNA vaccines, COVID-19 vaccine development.
  • Bioremediation and beneficial uses of microorganisms in agriculture and environment.

Frequently Tested Concepts

  • Fleming discovered penicillin (1928); it is effective only against bacteria, not viruses.
  • Vaccines work by stimulating the adaptive immune system to produce memory cells.
  • Rhizobium fixes nitrogen in legume root nodules (symbiotic); Azotobacter is free-living.
  • SARS-CoV-2 is an RNA virus; Hepatitis B is a DNA virus.
  • UIP launched in 1985; now covers 12 diseases; Mission Indradhanush launched in December 2014.

Vocabulary

Antibiotic

  • Pronunciation: /ˌæntɪbaɪˈɒtɪk/
  • Definition: A substance, originally produced by microorganisms such as fungi or bacteria, that can destroy or inhibit the growth of bacteria — ineffective against viruses.
  • Origin: From French antibiotique, from anti- (against) + Greek biōtikos (fit for life, from bios, life); first used in English in the 1850s, with modern medical usage from the 1940s following the development of penicillin.

Antigen

  • Pronunciation: /ˈæntɪdʒən/
  • Definition: Any substance — typically a protein on the surface of a pathogen — that is recognised as foreign by the immune system and triggers the production of antibodies.
  • Origin: From French antigène, from anti- (short for antibody) + -gène (producer, from Greek -genēs, born of); first recorded in 1905 in the Journal of the American Medical Association.

Probiotic

  • Pronunciation: /ˌprəʊbaɪˈɒtɪk/
  • Definition: A live microorganism — typically a bacterium such as Lactobacillus or Bifidobacterium — that, when consumed in adequate amounts, confers a health benefit on the host by supporting gut flora.
  • Origin: From pro- (for, in favour of, from Latin) + biotic (from Greek biōtikos, pertaining to life); first used in the 1950s as the conceptual opposite of antibiotic.

Key Terms

Antimicrobial Resistance

  • Pronunciation: /ˌæntɪmaɪˈkrəʊbiəl rɪˈzɪstəns/
  • Definition: The ability of microorganisms -- bacteria, viruses, fungi, and parasites -- to evolve and survive exposure to antimicrobial drugs (antibiotics, antivirals, antifungals, antiparasitics) that were previously effective against them, making infections progressively harder to treat and increasing the risk of disease spread, severe illness, and death. AMR occurs through natural evolutionary processes (random mutations, horizontal gene transfer between bacteria) but is dramatically accelerated by human misuse and overuse of antimicrobials. WHO estimates that by 2050, drug-resistant infections could cause 10 million deaths annually worldwide if unchecked, surpassing cancer as a cause of death.
  • Context: Alexander Fleming, in his 1945 Nobel Prize lecture for the discovery of penicillin, presciently warned: "There is the danger that the ignorant man may easily underdose himself and by exposing his microbes to non-lethal quantities of the drug make them resistant." Key resistant pathogens (superbugs): MRSA (Methicillin-Resistant Staphylococcus aureus), NDM-1 (New Delhi Metallo-beta-lactamase 1, named after the city where it was first identified in 2008, confers resistance to nearly all beta-lactam antibiotics including carbapenems -- last-resort drugs), XDR-TB (Extensively Drug-Resistant Tuberculosis), and CRE (Carbapenem-Resistant Enterobacteriaceae). India is among the world's largest consumers of antibiotics, driven by over-the-counter availability, self-medication, irrational prescription, and heavy agricultural/veterinary use. India's NAP-AMR 1.0 was launched on 19 April 2017, aligned with the WHO Global Action Plan; NAP-AMR 2.0 was launched in 2024 with updated multi-sectoral strategies. The Red Line Campaign (2016) marks prescription-only antibiotics with a red line on packaging. Schedule H1 (2013) restricts sale of certain antibiotics without prescription.
  • UPSC Relevance: GS3 (Science & Technology) and GS2 (Health). Prelims tests AMR definition, superbugs (MRSA, NDM-1 -- named after New Delhi), the distinction between antibiotics (target bacteria) and antivirals (target viruses -- antibiotics are useless against viral infections like flu and COVID), and Alexander Fleming (penicillin, 1928, Nobel Prize 1945). Mains frequently asks about AMR as a public health crisis -- causes (overuse, self-medication, over-the-counter availability without prescription, agricultural use in poultry/livestock), India's NAP-AMR (2017, updated 2024), ICMR AMR Surveillance Network, Red Line Campaign (2016), Schedule H1 restrictions, and the One Health approach to AMR (human + animal + environmental sectors). WHO classifies AMR as a top-10 global public health threat. Link to India's pharmaceutical industry (antibiotic production hub) and the tension between affordable medicine access and resistance prevention.

Herd Immunity

  • Pronunciation: /hɜːd ɪˈmjuːnɪti/
  • Definition: A form of indirect protection from an infectious disease that occurs when a sufficiently large proportion of a population becomes immune -- through vaccination or prior natural infection -- thereby reducing the probability of disease transmission to the remaining susceptible individuals who cannot be vaccinated (such as newborns, immunocompromised patients, and the elderly). The herd immunity threshold (HIT) is the minimum proportion of the population that must be immune to prevent sustained disease transmission; it depends on the disease's basic reproduction number (R0 -- the average number of people one infected person infects in a fully susceptible population).
  • Context: The concept was first discussed in 1894 by American veterinary scientist Daniel Elmer Salmon in the context of livestock disease resistance; applied to human epidemiology from the 1920s and mathematically formalised in the 1970s. The threshold formula is HIT = 1 - (1/R0). Key thresholds: measles (R0 ~12-18, HIT ~92-95% -- one of the highest, requiring near-universal vaccination), polio (R0 ~5-7, HIT ~80-86%), diphtheria (R0 ~6-7, HIT ~83-86%), COVID-19 (R0 varied by variant, 2-8+). The concept gained unprecedented public attention during the COVID-19 pandemic, with debate about whether herd immunity could be achieved through natural infection alone (the "Great Barrington Declaration" approach, October 2020) versus vaccination (the dominant public health strategy). India's COVID-19 vaccination drive (220+ crore doses) aimed to achieve sufficient population immunity to reduce severe disease and mortality.
  • UPSC Relevance: GS3 (Science & Technology) and GS2 (Health). Prelims may test the concept, the formula HIT = 1 - (1/R0), and disease-specific thresholds (measles ~95%, polio ~80-85%). Mains asks about herd immunity in the context of pandemic preparedness (COVID-19 experience), India's Universal Immunisation Programme (1985), Mission Indradhanush (targeting districts with <70% full immunisation), and vaccine hesitancy as a barrier to achieving herd immunity. Know that herd immunity protects the most vulnerable who CANNOT be vaccinated -- this ethical argument for universal vaccination is relevant for GS4. Also connects to India's role as "Pharmacy of the World" and Vaccine Maitri.